IMRN Stock - Immuron Limited
Unlock GoAI Insights for IMRN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.29M | $4.90M | $1.80M | $765,193 | $145,776 |
| Gross Profit | $4.77M | $3.34M | $1.74M | $523,502 | $-665,060 |
| Gross Margin | 65.4% | 68.1% | 96.4% | 68.4% | -456.2% |
| Operating Income | $-5,344,548 | $-5,801,118 | $-3,568,838 | $-2,869,855 | $-8,379,908 |
| Net Income | $-5,215,987 | $-6,936,957 | $-3,786,507 | $-2,854,254 | $-8,384,465 |
| Net Margin | -71.6% | -141.5% | -209.8% | -373.0% | -5751.6% |
| EPS | $-0.90 | $-1.22 | $-0.66 | $-0.50 | $-1.52 |
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Visit WebsiteEarnings History & Surprises
IMRNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q3 2025 | Aug 28, 2025 | $-0.01 | $-0.31 | -2219.5% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-0.01 | $-0.27 | -1922.7% | ✗ MISS |
Q4 2024 | Oct 2, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.57 | — | — |
Q2 2024 | Apr 29, 2024 | — | — | — | — |
Q1 2024 | Feb 27, 2024 | — | $-0.25 | — | — |
Q3 2023 | Aug 30, 2023 | — | — | — | — |
Q3 2023 | Aug 30, 2023 | — | $-0.11 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.12 | — | — |
Q3 2022 | Aug 31, 2022 | — | — | — | — |
Q3 2022 | Aug 30, 2022 | — | $-0.13 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.23 | — | — |
Q3 2021 | Sep 7, 2021 | — | — | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.35 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.80 | — | — |
Q3 2020 | Aug 30, 2020 | — | — | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.22 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-0.24 | — | — |
Q3 2019 | Aug 30, 2019 | — | — | — | — |
Latest News
Immuron shares are trading lower after topline results from a clinical trial of IMM‑124E did not achieve statistical significance on the primary endpoint.
📉 NegativeImmuron Announces A New Research Agreement With The Naval Medical Research Command And The Walter Reed Army Institute Of Research, Funded By U.S. Department Of Defense Subaward
📈 PositiveImmuron's IMM-529 IND Approved By FDA And Phase 2 Trial May Proceed
📈 PositiveImmuron Completes Minor Protocol Updates For IMM-529 IND Following FDA Request For Additional Clinical Information
📈 PositiveImmuron Reported Q1 Sales Growth Of 34% On Prior Comparative Period
📈 PositiveImmuron Submits IND To FDA For Oral IMM-529 Targeting Clostridioides Difficile, With Phase 2 Trial Planned In H1 2026 For CDI Treatment And rCDI Prevention
📈 PositiveImmuron Says It Is On Track To Exceed FY24 First-Quarter Sales; To Request End Of Phase 2 Meeting With FDA For IMM-124E
📈 PositiveImmuron Advances FDA Filings And Preps 2025 Launch Of New IBS Treatment ProIBS, Eyes October Results For Travelan US Military Trial
📈 PositiveReported Earlier, Immuron Partners With InvestorHub To Launch Interactive Investor Hub Enhancing Shareholder Communication And Engagement
📈 PositiveFrequently Asked Questions about IMRN
What is IMRN's current stock price?
What is the analyst price target for IMRN?
What sector is Immuron Limited in?
What is IMRN's market cap?
Does IMRN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IMRN for comparison